The Effect of COVID- 19 on the Market Access Landscape
February 9, 2021 @ 1:30 pm – 2:00 pm
Speakers: Carolyn Chamberlain, Blueprint Partnership and Mark Waker, MTW Consultancy Ltd
Convenor: An-hwa Lee, Research Partnership
This webinar focuses on the insights from one on one interviews with Payers (both national and regional level) across both the EU5 and US
Aimed at anyone involved with Pharma PMR, Insight and Analytics (both MROs and Pharma Co) wanting to understand the impact of COVID 19 on the pharma and payer landscape
Key take aways: We’ll be exploring key pertinent topics which will affect the entire Healthcare industry.
Namely – the direct impact of COVID. How budgets have been affected and the implications this will have on new drug approvals. We will uncover if there are any therapy areas that are ‘true’ winners – rare diseases, oncology? Which therapy areas are the losers? What does this mean for new products coming to market? We will focus on uncovering the reality and impact of COVID 19 and the implications on market access, the pharma industry, and ultimately patients!
We will provide all listeners with a view of landscape, the impact of COVID – access to new drugs. Sadly, it really is the ‘perfect storm’ – healthcare budget tighten, level of chronic illness increases, the economic crisis – all placing immense strain on healthcare services around the world.
A not to be missed webinar!
With a track record of more than 20+ years of experience in pharmaceutical market research, both client and agency side, working in a variety of roles.
Her career began at AstraZeneca Global where she led insights teams within CV and Oncology for over a decade. Her contributions helped drive the growth of key blockbusters. Carolyn is a well-known commercial market leader in qualitative and quantitative insight in both the UK and overseas. She is passionate about engaging with a diverse range of stakeholders and driving debate in our industry. We must continue to positively disrupt and transform our industry!
Over the last 15 years, she held senior commercial and leadership positions with IPSOS, Kantar Health and the Adelphi Group, whilst also being a key contributor to EphMra, PMRC and the BHBIA
MTW Consultancy Ltd
Mark is managing director of a market access consultancy, MTW Consultancy Ltd, specialising in advising small to medium sized pharmaceutical companies as well as governments on integrated pricing, reimbursement, access and health economic solutions to healthcare delivery. Mark has over twenty years’ industry experience working in a broad range of therapeutic areas with exposure to all stages of the product life cycle. Working with payers and market access stakeholders, projects undertaken range from early asset pipeline assessments through to LOE and life-cycle management access strategies. Mark also specialises in advising companies on how to optimally integrate and structure market access capabilities within their organisations.
Mark started off his career at Procter & Gamble then held marketing and market access roles at Merck and Nycomed before setting up his own consultancy in 2010